About
Technology
Issues
FAQ
Links
Official Page
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.